Venn Life Sciences Holdings Stock London S.E.
Equities
GB00B9275X97
Biotechnology & Medical Research
Sales 2023 | 56.04M 70.31M | Sales 2024 * | 62.91M 78.93M | Capitalization | 190M 239M |
---|---|---|---|---|---|
Net income 2023 | 16M 20.07M | Net income 2024 * | 8M 10.04M | EV / Sales 2023 | 2.88 x |
Net cash position 2023 * | 34.79M 43.65M | Net cash position 2024 * | 43.8M 54.95M | EV / Sales 2024 * | 2.33 x |
P/E ratio 2023 |
10.1
x | P/E ratio 2024 * |
22.4
x | Employees | - |
Yield 2023 * |
1.45% | Yield 2024 * |
0.84% | Free-Float | 60.77% |
Latest transcript on Venn Life Sciences Holdings
Managers | Title | Age | Since |
---|---|---|---|
Yamin Khan
CEO | Chief Executive Officer | 55 | 21-10-12 |
Ian O'Connell
FOU | Founder | 37 | 11-01-31 |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 22-06-07 | |
Cathal Friel
FOU | Founder | 59 | 11-01-31 |
Brendan Buckley
FOU | Founder | 73 | 18-11-30 |
1st Jan change | Capi. | |
---|---|---|
+26.28% | 48.09B | |
-3.99% | 40.43B | |
+45.32% | 40.62B | |
-6.20% | 28.36B | |
+6.36% | 24.89B | |
-21.47% | 19.01B | |
+27.58% | 12.09B | |
-2.75% | 11.8B | |
-2.02% | 11.88B |